INTRODUCTION {#sec1-1}
============

Rhabdomyosarcoma (RMS) is one of the most frequent soft tissue sarcomas. Paratesticular RMS is rare and consists 7% of all RMS.\[[@ref1]\] Paratesticular RMS represents the most common non-germinal malignant tumor in this site.\[[@ref2]\] Paratesticular RMS can develop from mesenchymal elements of the spermatic cord, the epididymis and the testicular envelopes, resulting in development of a painless scrotal mass. The clinical presentation includes a short history of painless swelling of the scrotum in a child or a young adult. Embryonal RMS is the predominant histological subtype and has a good prognosis.\[[@ref3]\] RMS is regarded as a highly malignant tumor with frequent recurrence. Spread of the tumor is mostly by lymphatics to the iliac and para-aortic nodes, but hematogeneous spread does occur, most commonly to the lungs and liver.\[[@ref2][@ref4]\] The efficacy of chemotherapy has diminished the role of surgery and radiotherapy following radical excision in early stages. The combined modalities of surgery, chemotherapy and radiation therapy have greatly improved the survival rate in paratesticular RMS without significant long-term complications. We herein report our institutional experience of 10 successive patients of paratesticular RMS being treated from July 2004 to December 2010.

MATERIALS AND METHODS {#sec1-2}
=====================

Patient population and initial evaluation {#sec2-1}
-----------------------------------------

We retrospectively reviewed the patients of paratesticular RMS from July 2004 to December 2010 treated in our institute. Total number of patients was 10. We reviewed the records of these patients to extract the following information: Age, sex, clinical symptoms, histology, testicular ultrasound, radiology \[contrast-enhanced computed tomography (CECT)/magnetic resonance imaging (MRI)\], tumor extent, and extent of surgical resection, Intergroup Rhabdomyosarcoma Study Group (IRSG) clinical group,\[[@ref5]\] TNM stage, chemotherapy (regimen, number of cycles), toxicity, response, recurrence, progression, metastases and death. Metastatic workup for distant metastases included CECT of the chest, abdomen and pelvis and bone scintigraphy. Laboratory studies included blood chemistry (electrolytes, liver and kidney function tests), and a complete blood count was performed.

Pathological review and staging {#sec2-2}
-------------------------------

Operative notes were reviewed to determine intraoperative suspicion of invasion, gross tumor extension into adjoining structures, and completeness of resection. Pathology reports were obtained for all patients and the tumors were classified according to histopathological subtype. Surgical assessment of the retroperitoneal lymph nodes was not used as a staging procedure. Staging was based on the surgical, radiological and pathological criteria as per TNM and IRSG clinical group system.

Treatment {#sec2-3}
---------

Surgery and CCT was used in the treatment. High inguinal orchidectomy was the primary surgical approach and systemic CCT was administered with VAC regimen comprising vincristine, adriamycin and cyclophosphamide 3 weekly for 4-6 cycles. All patients underwent primary surgery in form of high inguinal orchidectomy followed by systemic CCT with VAC regimen. The median number of CCT cycles was six.

Follow-up {#sec2-4}
---------

The period between the first complaint and diagnosis was registered as symptom duration. Survival, recurrence and progression information were collected through chart review, patient or relative contact. Response evaluation was noted both clinically and radiologically and response evaluation criteria in solid tumors (RECIST) was applied.\[[@ref6]\]

### Statistical analysis {#sec3-1}

SPSS v 15 was used for statistical analysis. The Kaplan-Meier survival analysis was done for analyzing progression-free survival (PFS) and overall survival (OS).\[[@ref7]\]

RESULTS {#sec1-3}
=======

Patient characteristics {#sec2-5}
-----------------------

Patient characteristics are summarized in [Table 1](#T1){ref-type="table"}. Between July 2004 and December 2010, 10 patients of paratesticular RMS were registered in our department. The median age of the patients was 16.5 years and ranges from 13 to 38 years. The median duration of symptoms was 5 months. On histopathological analysis, seven patients had embryonal RMS histology tumors and 3 patients had alveolar RMS histology tumors. On metastatic workup, retroperitoneal lymphadenopathy (RPLAP) was present in five patients, lung metastases in three patients and one patient had orbital metastases. Overall, four patients were in clinical group I, two patients in clinical group II and four patients in clinical group IV. On TNM staging, six patients were in Stage I and four patients were in Stage IV.

###### 

Patient characteristics, treatment details and outcome
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Clinical outcomes {#sec2-6}
-----------------

After treatment completion, patients were assessed for response both clinically and radiologically. Six patients were asymptomatic and four patients had significant improvement in symptoms. As per the RECIST criteria, six patients had complete response (CR) and four patients had partial response (PR). Mean duration of follow-up was 34 months, while median duration of follow-up was 20 months. Twenty month actuarial PFS of all patients was 53.0% \[[Figure 1](#F1){ref-type="fig"}\] and mean PFS was 48 months. Twenty-month actuarial overall survival (OS) was 55.0% and mean OS was 56 months with median OS not reached \[[Figure 2](#F2){ref-type="fig"}\].
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Treatment toxicity and compliance {#sec2-7}
---------------------------------

There were no surgical complications in form of postoperative deaths or wound complications. CCT toxicity was seen in seven patients in form of grade 1-2 hematological toxicity. All patients completed treatment with no significant toxicity or treatment interruption.

DISCUSSION {#sec1-4}
==========

Paratesticular RMS is rare and consists 7% of all RMS cases in adults.\[[@ref1]\] Embryonal RMS is the predominant histological subtype in 90% of paratesticular RMS and has a good prognosis.\[[@ref3]\] RMS is regarded as a highly malignant tumor with frequent recurrence. Spread of the tumor is mostly by lymphatics to the iliac and para-aortic nodes, but hematogenous spread does occur, most commonly to the lungs and liver.\[[@ref2][@ref4]\] The optimal management of paratesticular RMS remains unclear because of the rarity of the disease in adults. Treatment strategies reviewed in the literature include radical high inguinal orchidectomy, chemotherapy (CCT), radiotherapy (RT) and retroperitoneal lymph node dissection (RPLND).\[[@ref8][@ref9][@ref10]\]

Ferrari *et al*. reviewed 216 patients of paratesticular RMS.\[[@ref3]\] The histological subtype was embryonal RMS in 181 (84%), alveolar RMS in 18 (8%), spindle cells in 10 (5%), and "not otherwise specified" in seven (3%) of cases. In our series, seven patients (70%) of patients were diagnosed with embryonal RMS, whereas three patients (30%) had alveolar RMS.

Complete resection of the primary tumor was the treatment of choice in all patients; no patient underwent RPLND. The role of RPLND still remains controversial.\[[@ref11]\] Hermans and colleagues described 19 paratesticular RMS patients treated with RPLND, and claimed that a combination of RPLND and systemic CCT afforded a high cure rate.\[[@ref12]\] Ferrari and colleagues reported on 44 patients with paratesticular RMS who did not underwent RPLND.\[[@ref4]\] The authors considered that RPLND was unnecessary for localized disease because of the sensitivity afforded by computed tomography, the potential RPLND-associated morbidity, the low rate of retroperitoneal recurrence, and the presumed efficacy of CCT in controlling of microscopic disease. An alternative approach toward the treatment of clinically enlarged retroperitoneal lymph nodes involves the use of a more intensive adjuvant chemotherapy regimen. Such an approach is based on results obtained in the IRS-III trial, which showed that patients experienced poor outcomes if treated with RPLND followed by CCT.\[[@ref13]\] The 5-year survival rates were 69% and 96% in patients with clinically negative nodes treated with and without RPLND, respectively. CCT can control micrometastases into retroperitoneal nodes when a primary tumor has been completely resected. In our present series, no patient was treated with RPLND.

The role for adjuvant CCT in adults remains poorly understood.\[[@ref11][@ref14]\] Ferrari and colleagues reported that CCT was effective to treat childhood RMS, in adjuvant setting.\[[@ref3]\] Vincristine, dactinomycin, cyclophosphamide, adriamycin, epirubicin, ifosfamide, carboplatin and etoposide were used in different combinations, and with varying dose schedules, in the cited study. A metaanalysis of genitourinary sarcoma of 14 randomized trials showed that doxorubicin-based adjuvant CCT prolonged the time to local recurrence and distant failure, but the data was not statistically significant.\[[@ref15]\] Also, such treatment was associated with a considerable degree of toxicity. About a third of patients with paratesticular sarcomas die from metastatic disease. In our series five patients had RPLAP with four having systemic metastases. All patients received systemic CCT with VAC regimen in our study. The mean PFS and OS in our series was 48 months and 56 months, respectively. We believe CCT should be offered as a component of multimodal therapy in patients with paratesticular RMS to control retroperitoneal dissemination and to minimize such dissemination.

The OS rates of patients with pediatric RMS approached 70% with the combined therapy.\[[@ref5][@ref10]\] In a study evaluating RMS at all sites in 2600 patients, adults with RMS experienced significantly worse prognosis than the children.\[[@ref16]\] In another study, in which adult RMS patients also fared more poorly than children, the 5-year adult PFS and OS rates were 28% and 40%, respectively.\[[@ref17]\] Survival rate depends, with statistical significance, on tumor histology, diameter, stage and location, patient age, response to CCT and metastases status.\[[@ref17][@ref18]\]

CONCLUSIONS {#sec1-5}
===========

Paratesticular RMS is rare and aggressive neoplasm in young adults. The management is a paradigm of cooperation between clinicians, surgeons and pathologists from establishing diagnosis to organizing the therapeutic strategy. Radical high inguinal orchidectomy is the primary treatment. Systemic CCT is essential in both early and advanced disease and has resulted in improved survival outcomes. The improved response and survival in our series is attributed to multimodality and risk-adapted treatment approaches. With new techniques and drugs, there is a significant improvement of therapeutic standard and paratesticular RMS represent a model of therapeutic implementation and achievement in oncology.
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